Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26862272 | 0.85 | LMNA (0.60) | LMNAHTR2BTHRBUSP2TP53 | |
| SCHEMBL21361595 | 0.84 | LMNA (0.61) | LMNAHTR2BTHRBUSP2TP53 | |
| SCHEMBL21361620 | 0.84 | LMNA (0.57) | LMNAHTR2BTHRBUSP2TP53 | |
| SCHEMBL4457699 | 0.82 | RAB9A (0.59) | LMNAHTR2BTHRBUSP2TP53 | |
| SCHEMBL14895871 | 0.82 | LMNA (0.57) | LMNAHTR2BTHRBUSP2TP53 | |
| SCHEMBL26295449 | 0.81 | LMNA (0.53) | LMNAHTR2BTHRBUSP2TP53 | |
| SCHEMBL14136368 | 0.81 | RAB9A (0.49) | LMNATHRBUSP2TP53MAPT | |
| SCHEMBL1128181 | 0.80 | RAB9A (0.62) | LMNAHTR2BTHRBUSP2TP53 | |
| SCHEMBL5014849 | 0.80 | LMNA (0.70) | LMNAHTR2BTHRBUSP2TP53 | |
| SCHEMBL20304443 | 0.80 | RAB9A (0.48) | LMNAHTR2BTHRBUSP2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | KEZAR LIFE SCIENCES (US) | 2023-02-14 | — | — | US | disclosed |
| US-20210078974-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2021-03-18 | — | — | US | disclosed |
| US-7553846-B2 | 2-alkylbenzoxazole carboxamides as 5-HT3 modulators | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20080214601-A1 | 2-ALKYLBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | AMR TECHNOLOGY, INC. (US) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | SEC61B, SEC61A1, SEC61G | LMNA 4550/4885HTR2B 3980/4885THRB 1059/4885 |
| US-20210078974-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | LMNA 4555/4885HTR2B 3721/4885THRB 984/4885 |
| US-20080214601-A1 | 2-ALKYLBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | HTR3E, HTR3C, HTR3A | LMNA 2774/4885HTR2B 6/4885THRB 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.